Molecular Biology Research Center, School of Life Science and State Key Laboratory of Medical Genetics of China, Central South University, Changsha, Hunan 410078, China.
Biomed Res Int. 2013;2013:964743. doi: 10.1155/2013/964743. Epub 2013 Jul 1.
To date, lung cancer is the leading cause of cancer-related death worldwide, among which nonsmall cell lung cancer (NSCLC) comprises about 85%. Taking into account the side effects of surgery, radiation, platinum-based doublet chemotherapy, and the growth self-sufficiency characteristic of cancer cells, drugs have been discovered toward growth factor receptor (GFR) to treat NSCLC. As expected, these drugs provide a greater benefit. To increase the efficacy of such growth factor receptor tyrosine kinase inhibitors (RTKIs), coinhibition of GFR signaling pathways and combination of inhibitors along with radiation or chemotherapy have drew intense insight. Although clinical trials about single-agent RTKIs or their combination strategies suggest their increase potency against cancer, they are not beyond adverse effects, and sometimes the effects are more deadly than chemotherapy. Nevertheless the hope for RTKIs may be proved true by further researches and digging deep into cancer therapeutics.
迄今为止，肺癌是全世界癌症相关死亡的主要原因，其中非小细胞肺癌 (NSCLC) 约占 85%。考虑到手术、放疗、铂类双联化疗以及癌细胞生长自给自足的特点，人们已经发现了针对生长因子受体 (GFR) 的药物来治疗 NSCLC。不出所料，这些药物提供了更大的益处。为了提高这些生长因子受体酪氨酸激酶抑制剂 (RTKIs) 的疗效，GFR 信号通路的联合抑制以及抑制剂与放疗或化疗的联合应用引起了广泛关注。尽管关于单药 RTKIs 或其联合策略的临床试验表明它们对癌症的疗效增强，但它们并非没有不良反应，有时这些作用比化疗更致命。然而，通过进一步的研究和深入挖掘癌症治疗方法，RTKIs 的希望可能会被证明是正确的。
